PriMera Scientific Surgical
Research and Practice
Volume 8 Issue 3 September 2026
DOI: 10.56831/PSSRP-08-327
ISSN: 2836-0028

Obsessive-Compulsive Disorder (OCD): Integrating Natural Ingredients as Adjuncts or Alternatives to Pharmacologic Therapy

Type: Review Article
Received: June 22, 2026
Published: September 02, 2026

Citation:
Christina Rahm. "Obsessive-Compulsive Disorder (OCD): Integrating Natural Ingredients as Adjuncts or Alternatives to Pharmacologic Therapy". PriMera Scientific Surgical Research and Practice 8.3 (2026): 29-35.

Christina Rahm*

DRC VENTURES LLC, USA

***Corresponding Author:** Christina Rahm, DRC VENTURES LLC, USA.

Abstract

Obsessive-Compulsive Disorder (OCD) is a persistent and disabling neuropsychiatric condition that is manifested by intrusive thoughts (obsessions) and repetitive actions (compulsions). The general therapy involves cognitive-behavioral therapy (CBT), exposure and response prevention (ERP), and pharmacologic therapy with selective serotonin reuptake inhibitors (SSRIs). Although effective, most patients respond partially, relapse, or have adverse effects, and this has indicated the interest of natural ingredients as an adjunctive or different therapy. In this paper, the role of natural compounds, such as amino acids, antioxidants, anti-inflammatory agents, and gut-modulating substances, in OCD management is assessed. Critical issues include mechanisms, clinical relevance, and integration with pharmaceutical agents. Although natural therapies might not substitute pharmacologic treatment in moderate-severe OCD, they have been shown to improve outcomes when employed in an adjunctive manner. A multimodal, integrative approach is an advisable treatment strategy to maximize symptom management, minimize side effects, and enhance long-term prognosis.

Introduction

Obsessive-Compulsive Disorder (OCD) is a condition that has a prevalence of 1-3 percent of the world population and is characterized by high levels of functional impairment and psychiatric comorbidity (Stein et al., 2025). It can be characterized by frequent obsessions and/or compulsions, which are time-consuming and upsetting (Brock et al., 2026). It typically presents during adolescence or early adulthood, and its progression is chronic and relapsing, making it long-lasting and difficult to manage. OCD pathophysiologically is a dysfunction of cortico-striato-thalamo-cortical (CSTC) circuits, and there are problems with the neurotransmission of serotonin, dopamine, and glutamate (Jalal et al., 2023). Despite first-line pharmacologic and psychotherapeutic therapy, the lack of efficacy and tolerability has prompted discussion of the use of complementary methods, such as natural ingredients that act via neurobiological and metabolic pathways.

Pathophysiology and Clinical Framework

Obsessive-compulsive disorder (OCD) is widely understood as a multifactorial condition influenced by an interplay of genetic, neurobiological, and environmental factors. Genetic studies consistently

demonstrate an increased risk among first-degree relatives, suggesting a heritable component to the disorder. From a neurobiological perspective, neuroimaging research has repeatedly identified hyperactivity in key regions of the brain, particularly the orbitofrontal cortex and the caudate nucleus. These structures are integral components of the cortico-striato-thalamo-cortical (CSTC) circuitry, which is responsible for regulating decision-making, behavioral control, and habit formation (Blanco-Vieira et al., 2023). Dysregulation within this circuit is believed to contribute to the hallmark features of OCD, including the inability to effectively suppress intrusive thoughts and the persistence of repetitive, compulsive behaviors. Additionally, environmental influences such as early life stress, trauma, or infections may further interact with these underlying vulnerabilities, potentially triggering or exacerbating symptom onset and severity. Together, these factors highlight the complex and interconnected mechanisms that drive the development and progression of OCD.

Serotonin dysregulation is often considered central to the pathophysiology of OCD, as evidenced by the clinical effectiveness of selective serotonin reuptake inhibitors (SSRIs) in reducing symptom severity at the neurochemical level. However, emerging research suggests that OCD is not solely a serotonergic disorder. Accumulating data indicate that disruptions in glutamatergic signaling, particularly within the cortico-striato-thalamo-cortical (CSTC) circuitry, as well as alterations in dopaminergic pathways, play a significant role in symptom expression—especially in relation to compulsive behaviors, reinforcement learning, and habit formation (Jalal et al., 2023). These neurotransmitter imbalances contribute to the persistence and rigidity of behavioral patterns seen in affected individuals.

In addition to neurotransmitter involvement, there is growing recognition of broader biological contributors, including oxidative stress, neuroinflammation, and mitochondrial dysfunction. These factors may exacerbate neuronal dysregulation, impair cellular energy production, and further disrupt communication between key brain regions involved in cognitive and emotional regulation. From a clinical standpoint, OCD presents with a wide spectrum of obsessions (intrusive, distressing thoughts) and compulsions (repetitive behaviors or mental acts), with varying degrees of insight or awareness among patients. Some individuals recognize their thoughts and behaviors as irrational, while others may have limited insight, which can complicate treatment. Diagnosis therefore requires a comprehensive and nuanced evaluation, incorporating standardized diagnostic criteria, assessment of symptom severity and functional impairment, and careful exclusion of other psychiatric or medical conditions that may present with overlapping features.

Conventional Pharmacologic Treatment

Selective serotonin reuptake inhibitors (SSRIs) are considered the primary pharmacologic agents in the treatment of OCD, as they increase serotonin availability within the synaptic cleft and help modulate dysfunctional signaling pathways. Commonly used SSRIs include fluoxetine, sertraline, and fluvoxamine, all of which have demonstrated efficacy in reducing obsessive thoughts and compulsive behaviors. These medications are regarded as first-line therapy and are typically prescribed at higher doses and for longer durations compared to their use in depressive disorders, reflecting the more persistent and treatment-resistant nature of OCD (Abramowitz et al., 2026).

While SSRIs have been shown to significantly alleviate symptom severity in many patients, their effects are often gradual and may take several weeks to become clinically noticeable. Importantly, they do not produce a universal response. A substantial proportion of individuals experience only partial improvement, and some may not respond at all. This variability in treatment response highlights the complexity of OCD pathophysiology and suggests that serotonergic modulation alone may be insufficient for full symptom resolution. As a result, combination approaches such as augmenting SSRIs with other pharmacologic agents or integrating evidence-based psychotherapies like cognitive behavioral therapy (CBT), particularly exposure and response prevention (ERP) are often necessary to achieve more optimal and sustained outcomes.

The strong evidence base and well-established dosing protocols are among the primary advantages of pharmacologic therapy, as they allow for standardized, reproducible, and clinically consistent use across diverse patient populations. These treatments have been extensively studied in controlled trials, providing clinicians with clear guidelines for initiation, titration, and long-term manage-

ment. This level of standardization helps ensure a predictable framework for care and supports their role as a cornerstone in OCD treatment strategies. However, pharmacologic therapy is not without limitations. One notable drawback is the delayed onset of therapeutic effects, with many patients requiring several weeks or even months before experiencing meaningful symptom improvement. Additionally, side effects are relatively common and may include gastrointestinal disturbances, sleep disruptions, weight changes, and sexual dysfunction, all of which can impact adherence to treatment. There is also the concern of incomplete response, where patients may experience only partial relief of symptoms. Furthermore, discontinuation of medication can be associated with a risk of relapse, particularly if underlying neurobiological and behavioral factors are not concurrently addressed. These considerations highlight the importance of individualized treatment planning and, in many cases, the integration of pharmacologic therapy with behavioral and supportive interventions to achieve more durable outcomes.

Natural Ingredients in OCD Management

Natural ingredients may offer supportive benefits in OCD by targeting multiple biological pathways involved in neurotransmission, stress regulation, and cognitive control. Unlike single-target pharmaceutical approaches, many of these compounds work across several systems simultaneously, which may be relevant given the multifactorial nature of OCD. L-tyrosine and L-phenylalanine serve as amino acid precursors to dopamine and norepinephrine neurotransmitters that play critical roles in attention, motivation, and executive function. By supporting catecholamine synthesis, these compounds may help improve cognitive flexibility and top-down control, which are often impaired in individuals with OCD. This can be particularly relevant for reducing the rigidity of thought patterns and enhancing the ability to shift away from intrusive thoughts. L-theanine, an amino acid commonly found in green tea, has been shown to promote relaxation without sedation by increasing GABAergic activity, while also influencing serotonin and dopamine levels. This contributes to a calming effect on the central nervous system, which may help reduce anxiety intensity and improve emotional regulation two key components in managing obsessive thought loops and compulsive responses.

Additionally, Mucuna pruriens, a natural source of L-DOPA, may further support dopaminergic signaling, particularly within the cortico-striato-thalamo-cortical (CSTC) circuitry implicated in OCD. By enhancing dopamine availability, it may help modulate reward processing and habit formation pathways, potentially reducing the reinforcement of compulsive behaviors (Lampariello et al., 2012). Beyond neurotransmitter support, many natural compounds also exhibit antioxidant and anti-inflammatory properties, which may help address emerging contributors to OCD such as oxidative stress and neuroinflammation. While these ingredients are not intended to replace standard treatments, they may serve as complementary strategies to support overall neurochemical balance, resilience, and symptom management when used as part of a comprehensive, individualized approach.

Antioxidants and anti-inflammatory compounds play a critical role in addressing underlying biological contributors to OCD, particularly oxidative stress and neuroinflammation, both of which have been increasingly implicated in the disorder's pathophysiology. Elevated oxidative stress can disrupt neuronal signaling, damage cellular structures, and impair mitochondrial function, while chronic neuroinflammation may alter neurotransmitter balance and contribute to dysfunction within key brain circuits such as the cortico-striato-thalamo-cortical (CSTC) loop. By targeting these processes, antioxidant and anti-inflammatory agents may help create a more stable neurological environment. Vitamin C is a potent water-soluble antioxidant that helps neutralize free radicals and regenerate other antioxidants within the body. It also plays a role in neurotransmitter synthesis, including dopamine and norepinephrine, thereby supporting overall brain function. Curcumin, a bioactive compound found in turmeric, has demonstrated strong anti-inflammatory and neuroprotective properties, including the ability to modulate inflammatory cytokines, reduce microglial activation, and influence serotonin and dopamine pathways. Similarly, resveratrol and quercetin are polyphenolic compounds known for their capacity to reduce oxidative damage, enhance mitochondrial efficiency, and support cellular signaling pathways involved in mood regulation and cognitive function. Trace minerals, including bioavailable forms of silicon, also contribute to neurological stability. Silicon has been associated with structural support of connective tissues and may play a role in detoxification processes, particularly in binding and facilitating the removal of certain environmental toxins. By reducing toxic burden and supporting cellular integrity, these minerals may indirectly support neuronal communication and resilience.

In addition, glutamate-modulating compounds such as N-acetylcysteine (NAC) have gained attention for their role in OCD management. NAC serves as a precursor to glutathione, one of the body's most important endogenous antioxidants, and helps regulate glutamate levels in the brain. By modulating excitatory neurotransmission particularly in regions involved in compulsive behavior NAC may help reduce the intensity and frequency of compulsions. Its dual role in restoring redox balance and stabilizing neurotransmitter activity makes it a particularly promising adjunctive compound in addressing both the biochemical and behavioral dimensions of OCD. Collectively, these natural compounds provide a multi-layered approach, supporting antioxidant defenses, reducing inflammation, enhancing detoxification pathways, and promoting more balanced neurotransmitter activity. While not a replacement for conventional therapies, they may offer meaningful complementary support in a comprehensive, systems-based approach to managing OCD.

Another significant and increasingly studied target of natural interventions in OCD is the gut-brain axis, a bidirectional communication network linking the gastrointestinal system with the central nervous system. The gut microbiome plays a critical role in regulating neurotransmitter production, immune signaling, and even stress responsiveness. Prebiotics and probiotics can help support a more balanced microbial environment, which in turn may influence mood and behavior. Certain probiotic strains have been shown to contribute to the production and regulation of neurotransmitters such as serotonin of which a large proportion is synthesized in the gut as well as GABA and short-chain fatty acids that support brain function. Additionally, a healthy microbiome helps regulate immune activity and reduce systemic inflammation, both of which are relevant given the role of neuroinflammation in OCD. By improving gut integrity and reducing inflammatory signaling, these interventions may help stabilize communication along the gut-brain axis and support more consistent emotional and cognitive regulation. Mitochondrial function is another important area of focus, as neurons are highly energy-dependent cells that require efficient ATP production to maintain signaling, plasticity, and repair processes. Compounds such as NAD^+ (nicotinamide adenine dinucleotide) play a central role in cellular energy metabolism, redox balance, and DNA repair. Supporting NAD^+ levels may enhance mitochondrial efficiency, reduce oxidative stress, and improve overall cellular resilience, which can be particularly beneficial in conditions associated with chronic stress and neuroinflammation. D-ribose, a naturally occurring sugar involved in ATP synthesis, may further support energy replenishment at the cellular level, helping neurons recover more efficiently from metabolic stress.

Together, these mitochondrial-supporting compounds may contribute to improved cognitive function, mental clarity, and stress tolerance by ensuring that brain cells have the energy required to function optimally. When combined with gut-focused interventions, this creates a more comprehensive, systems-based approach supporting not only neurotransmitter balance and immune regulation, but also the foundational energy systems that drive brain performance. While more research is still evolving, these strategies highlight the importance of looking beyond single pathways and instead addressing the interconnected systems that influence mental health outcomes.

Integration of Nutraceutical Systems

The combination of nutraceutical systems, like those outlined in the material, reflects a more comprehensive and systems-based approach to supporting individuals with OCD. Rather than targeting a single pathway, these formulations are designed to address multiple underlying biological contributors simultaneously such as neurotransmitter imbalance, oxidative stress, neuroinflammation, mitochondrial dysfunction, and gut dysbiosis. This multi-target strategy aligns with the complex and multifactorial nature of OCD, where disruptions occur across interconnected neurological and physiological systems. For example, amino acid and botanical extract formulations play a foundational role in supporting neurotransmitter synthesis and regulation. Ingredients such as L-tyrosine, L-phenylalanine, and Mucuna pruriens contribute to dopamine production, which is essential for motivation, reward processing, and habit regulation. At the same time, compounds like L-theanine and certain polyphenols can support serotonin and GABA activity, promoting a calmer mental state, improved emotional regulation, and reduced anxiety-driven thought patterns. This balanced neurotransmitter support may help improve cognitive flexibility and reduce the intensity of obsessive-compulsive loops.

In parallel, formulations that focus on gut health through the inclusion of prebiotics and probiotics help restore microbiome diversity and integrity. A more balanced gut environment supports not only serotonin production but also immune regulation and reduced

systemic inflammation, both of which have downstream effects on brain function. Improved gut barrier integrity may also limit the translocation of inflammatory compounds that could otherwise contribute to neuroinflammatory processes. Mineral-based support further enhances this framework by contributing to neuronal stability and proper signal transmission. Essential minerals such as magnesium, zinc, and trace elements help regulate excitatory and inhibitory signaling within the nervous system, ensuring that neural communication remains balanced and not overly stimulated. This is particularly important in OCD, where excessive excitatory activity especially involving glutamate has been implicated in symptom persistence.

Additionally, many of these nutraceutical systems incorporate antioxidants and mitochondrial-supporting compounds, which help protect neurons from oxidative damage while improving cellular energy production. This supports overall brain resilience, allowing neural circuits involved in decision-making, impulse control, and emotional processing to function more efficiently. Together, these integrated systems move beyond symptom suppression and instead aim to support the underlying biological terrain contributing to OCD. By addressing neurotransmitter balance, inflammation, gut-brain communication, and cellular energy simultaneously, this approach may provide more sustainable support for mental well-being and cognitive function when used alongside appropriate clinical care.

Natural vs. Pharmaceutical Approaches

There are both natural and pharmaceutical approaches to managing OCD, each with distinct advantages and limitations that often make them complementary rather than mutually exclusive. Natural therapies are frequently associated with a lower side-effect profile and a broader, systems-based mechanism of action. By influencing multiple biological pathways simultaneously such as neurotransmitter balance, inflammation, oxidative stress, and gut-brain signaling these interventions may support overall neurological resilience and long-term mental well-being. They are often perceived as more "holistic," which can increase patient acceptance and adherence, particularly among individuals seeking alternative or integrative care options. Additionally, natural approaches may be better suited for long-term use in some individuals due to their generally milder side-effect burden. However, natural therapies are not without limitations. One of the primary challenges is the relative lack of large-scale, well-controlled randomized clinical trials compared to pharmaceutical agents. This can make it more difficult to standardize protocols or predict outcomes with the same level of certainty. Variability in product quality, sourcing, and bioavailability can also impact effectiveness, especially in an unregulated supplement landscape. Furthermore, natural interventions often require a longer duration to produce noticeable effects, which may be a barrier for individuals seeking more immediate symptom relief.

On the other hand, pharmaceutical therapies particularly SSRIs and other evidence-based medications have a robust body of clinical research supporting their use and are considered essential in moderate-to-severe OCD cases. They can provide more rapid and targeted symptom reduction, especially when intrusive thoughts and compulsive behaviors significantly impair daily functioning. However, these treatments can be associated with side effects such as gastrointestinal disturbances, sleep issues, emotional blunting, and sexual dysfunction, which may affect long-term adherence. Additionally, a significant proportion of patients experience only partial remission, highlighting that pharmacologic intervention alone may not fully address the complexity of the disorder. Taken together, these considerations suggest that an integrative approach combining the precision and evidence base of pharmaceuticals with the multi-target, supportive nature of natural therapies may offer the most comprehensive strategy. Tailoring interventions to the individual, while considering factors such as symptom severity, biology, lifestyle, and preferences, is key to optimizing outcomes and supporting sustainable mental health improvements.

Synergistic Integration: A Multimodal Approach

The combination of natural ingredients with traditional pharmacologic therapies represents a promising direction for improving outcomes in OCD, particularly given the condition's complex and multifactorial nature. Rather than relying on a single mechanism of action, this integrative approach allows for the simultaneous targeting of multiple neurobiological pathways. For example, while SSRIs primarily act by increasing serotonin availability and modulating serotonergic signaling, adjunctive natural compounds such as N-ace-

tylcysteine (NAC), polyphenols, and other antioxidants can address additional contributors like oxidative stress, neuroinflammation, glutamate dysregulation, and mitochondrial inefficiency. This layered strategy may help enhance overall treatment response, especially in individuals who experience only partial improvement with medication alone.

NAC, in particular, has been studied for its ability to regulate glutamatergic activity and replenish intracellular glutathione levels, thereby supporting both neurotransmitter balance and antioxidant defenses. When used alongside SSRIs, it may help modulate excitatory signaling within key brain circuits, potentially reducing compulsive behaviors more effectively than serotonergic modulation alone. Similarly, antioxidants such as curcumin, resveratrol, and quercetin may help stabilize neuronal function by reducing inflammatory signaling and protecting against oxidative damage, which can otherwise impair neurotransmission and worsen symptom persistence. This multimodal approach closely aligns with the principles of personalized medicine, which emphasize tailoring interventions based on an individual's unique biology, symptom profile, and environmental exposures. By combining pharmacologic and natural therapies, clinicians may be able to use lower doses of medications in some cases, potentially reducing the risk or severity of side effects while still achieving therapeutic benefit. This can also improve patient adherence, particularly for individuals who are sensitive to medications or prefer a more integrative care model.

Furthermore, the addition of evidence-based psychotherapies such as cognitive behavioral therapy (CBT) and exposure and response prevention (ERP) further strengthens this framework. While pharmacologic and nutraceutical strategies support the underlying biology, psychotherapy directly addresses maladaptive thought patterns, behavioral conditioning, and cognitive distortions that sustain OCD. Together, these approaches create a comprehensive treatment model that targets both the biological and psychological dimensions of the disorder. Overall, integrating natural compounds with conventional pharmacologic and behavioral therapies offers a more adaptive and patient-centered strategy. By addressing multiple layers of dysfunction simultaneously, this approach has the potential to improve symptom control, enhance quality of life, and support more sustainable, long-term outcomes.

Conclusion

Obsessive-compulsive disorder is a complex and multifactorial condition that requires a comprehensive, individualized approach to care. While pharmacologic therapies remain a cornerstone of treatment particularly in moderate to severe cases—they do not fully address the wide range of biological and functional disruptions associated with OCD. Emerging evidence supports the role of natural compounds as complementary interventions, capable of targeting additional pathways such as oxidative stress, neuroinflammation, mitochondrial function, neurotransmitter synthesis, and gut–brain axis signaling. By supporting these underlying systems, natural therapies may enhance overall neurological resilience and contribute to more balanced cognitive and emotional regulation.

Importantly, these interventions are best positioned within an integrative treatment model rather than as standalone therapies. When combined with evidence-based pharmacologic treatments and psychotherapeutic approaches, such as cognitive behavioral therapy and exposure and response prevention, they offer a more complete strategy that addresses both the biological and behavioral dimensions of the disorder. This multimodal framework aligns with the principles of personalized medicine, allowing treatment to be tailored to the individual's unique physiology, symptom profile, and response patterns. Looking forward, further large-scale, well-controlled clinical studies are needed to better define standardized protocols, optimize dosing strategies, and validate the efficacy of specific natural compounds in OCD management. As research continues to evolve, integrative approaches that combine conventional and natural therapies hold significant potential to improve outcomes, reduce long-term disease burden, and support a more sustainable and patient-centered model of mental health care.

References

1. Abramowitz JS., et al. "Management of obsessive-compulsive disorder in adults". BMJ 392 (2026).
2. Akosile AY, Tiyatiye B and Akosile W. "A systematic review on the prevalence of comorbid substance use disorder in obsessive-compulsive disorder among the general population". Psychoactives 4.1 (2025): 2.
3. Aymerich C., et al. "Prevalence and correlates of the concurrence of autism spectrum disorder and obsessive compulsive disorder

in children and adolescents: a systematic review and meta-analysis". Brain Sciences 14.4 (2024): 379.

4. Blanco-Vieira T., et al. "The genetic epidemiology of obsessive-compulsive disorder: a systematic review and meta-analysis". Translational Psychiatry 13.1 (2023): 230.
5. Brock H, Rizvi A and Hany M. "Obsessive-Compulsive Disorder". StatPearls (2026).
6. Heydarikhayat S., et al. "Prevalence of obsessive-compulsive disorder in the older person: a systematic review and meta-analysis". BMC Geriatrics 24.1 (2024): 874.
7. Jalal B, Chamberlain SR and Sahakian BJ. "Obsessive-compulsive disorder: Etiology, neuropathology, and cognitive dysfunction". Brain and Behavior 13.6 (2023): e3000.
8. Lampariello LR., et al. "The Magic Velvet Bean of Mucuna pruriens". Journal of Traditional and Complementary Medicine 2.4 (2012): 331-339.
9. Mayo Clinic. "Obsessive-compulsive disorder (OCD)". (2023).
10. Sadowska A and Świderski F. "Sources, bioavailability, and safety of silicon derived from foods and other sources added for nutritional purposes in food supplements and functional foods". Applied Sciences 10.18 (2020): 6255.
11. SoleimanvandiAzar N., et al. "Prevalence of obsessive-compulsive disorders (OCD) symptoms among health care workers in COVID-19 pandemic: a systematic review and meta-analysis". BMC Psychiatry 23.1 (2023): 862.
12. Stein DJ., et al. "Obsessive-compulsive disorder in the World Mental Health surveys". BMC Medicine 23.1 (2025): 416.
13. Ujjwal P, Sanjita D and Kumar FN. "A comprehensive review on obsessive-compulsive disorder: An update". Pharmacophore 15.2 (2024): 54-62.